[Form 4] Kura Oncology, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Kura Oncology, Inc. (KURA) President and CEO Troy E. Wilson reported the vesting of 182,500 shares of common stock on 11/13/2025. These shares relate to performance-based restricted stock units (PSUs) originally granted on May 31, 2023, which vest upon achievement of specified development milestones and the one-year anniversary of each milestone, subject to continued service. The filing states that the performance criteria for one development milestone were met on November 13, 2025, triggering vesting of one-sixth of the underlying shares at a price of $0 per share. Following this transaction, Wilson beneficially owns 429,353 shares directly, 279,194 shares indirectly through the One Fish Two Fish Revocable Trust, and 300,000 shares indirectly through the Lorax Charitable Remainder Unitrust.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WILSON TROY EDWARD

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/13/2025		A(1)		182,500	A	$0	429,353	D
Common Stock								279,194	I	by One Fish Two Fish Revocable Trust
Common Stock								300,000	I	by Lorax Charitable Remainder Unitrust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents 1/3rd of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The performance criteria for one specified development milestone was determined to be met on November 13, 2025, resulting in the vesting of 1/6th of the underlying shares.

	Teresa Bair, Attorney-in-fact for Troy E. Wilson	11/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Kura Oncology (KURA) report for its CEO?

Kura Oncology reported that President and CEO Troy E. Wilson acquired 182,500 shares of common stock on 11/13/2025 upon vesting of performance-based restricted stock units at a price of $0 per share.

What are the terms of the performance-based RSUs reported by Kura Oncology (KURA)?

The performance-based RSUs were granted on May 31, 2023. Each unit represents the right to receive one share of common stock upon achievement of three specified development milestones and the one-year anniversary of each milestone, subject to the CEO’s continuous service.

Why did 182,500 Kura Oncology (KURA) shares vest on November 13, 2025?

The filing explains that the performance criteria for one specified development milestone were determined to be met on November 13, 2025, resulting in the vesting of one-sixth of the underlying PSU shares, totaling 182,500 shares.

How many Kura Oncology (KURA) shares does the CEO beneficially own after this transaction?

After the reported transaction, Troy E. Wilson beneficially owns 429,353 shares directly, 279,194 shares indirectly through the One Fish Two Fish Revocable Trust, and 300,000 shares indirectly through the Lorax Charitable Remainder Unitrust.

Was there any cash paid for the vested Kura Oncology (KURA) shares?

No cash was paid for these shares; the 182,500 shares of common stock were acquired at a reported price of $0 per share upon vesting of the PSUs.

What role does Troy E. Wilson hold at Kura Oncology (KURA)?

Troy E. Wilson is both a Director and the President and CEO of Kura Oncology, Inc. as indicated in the filing.